NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2
June 20, 2023 01:00 ET
|
NMD Pharma
NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2 Results from the study establish, for the...
NMD Pharma appoints Daniel Brennan as SVP, Corporate and Commercial Strategy
June 01, 2023 07:00 ET
|
NMD Pharma
Daniel Brennan brings over 25 years of strategic commercial experience leading public and private rare disease and CNS biopharma companies Aarhus, Denmark, 1 June 2023 – NMD Pharma A/S, a...
NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343
May 23, 2023 07:00 ET
|
NMD Pharma
NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343 NMD1343 is a novel small molecule inhibitor of the muscle-specific chloride ion channel, the ClC-1 ion...
NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343
May 23, 2023 01:00 ET
|
NMD Pharma
NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343 NMD1343 is a novel small molecule inhibitor of the muscle-specific chloride ion channel, the ClC-1 ion...
Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors
January 03, 2023 07:00 ET
|
NMD Pharma
Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors Brings 30 years of experience building private and public development-stage and commercial biopharmaceutical companies and has...
Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors
January 03, 2023 01:00 ET
|
NMD Pharma
Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors Brings 30 years of experience building private and public development-stage and commercial biopharmaceutical companies and has...
NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3
December 14, 2022 07:00 ET
|
NMD Pharma
NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3 Aarhus, Denmark, 14 December 2022 – NMD Pharma A/S, a...
NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3
December 14, 2022 01:00 ET
|
NMD Pharma
NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3 Aarhus, Denmark, 14 December 2022 – NMD Pharma A/S, a...
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis
October 11, 2022 07:00 ET
|
NMD Pharma
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis Data provides first clinical proof of the mechanism of action of NMD Pharma’s...
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis
October 11, 2022 01:00 ET
|
NMD Pharma
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis Data provides first clinical proof of the mechanism of action of NMD Pharma’s...